아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

teva b.v. - atazanavir sulfate - capsule, hard - 200 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (
4 pi mutations). there are very limited data available from children aged 6 to less than 18 years

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

teva b.v. - atazanavir sulfate - capsule, hard - 300 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (
4 pi mutations). there are very limited data available from children aged 6 to less than 18 years (

미국 - 영어 - NLM (National Library of Medicine)

american health packaging - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsule is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 6 years and older weighing at least 15 kg. limitations of use: - atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of atazanavir capsules/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir capsules are contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)]. - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening

미국 - 영어 - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsule  is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: - atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see use in specific populations (8.4)].   - use of atazanavir capsules with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir capsules are contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)]

미국 - 영어 - NLM (National Library of Medicine)

cipla usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: - atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.[see use in specific populations (8.4)] . - use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concen

미국 - 영어 - NLM (National Library of Medicine)

major pharmaceuticals - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsule  is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 6 years and older weighing at least 15 kg. limitations of use: atazanavir capsules are contraindicated: table 6 displays drugs that are contraindicated with atazanavir capsules.   drug class drugs within class that are contraindicated with atazanavir capsules clinical comment alpha 1-‑adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if atazanavir capsules are coadministered with ritonavir.   pimozide potenti

케냐 - 영어 - Pharmacy and Poisons Board

shanghai desano bio-pharmaceuticals co. ltd 4th floorblock no.1 1479 zhangheng road china - atazanavir (as sulfate), ritonavir - tablet - 300 mg/ 100 mg - antivirals for systemic use: combinations of

싱가포르 - 영어 - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - atazanavir sulfate 170.83 mg eqv atazanavir - capsule - 150 mg - atazanavir sulfate 170.83 mg eqv atazanavir 150 mg

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - atazanavir sulfate 170.84mg equivalent to 150 mg atazanavir - capsule - 150 mg - active: atazanavir sulfate 170.84mg equivalent to 150 mg atazanavir excipient: capsugel blue 2614 capsugel blue 3546 capsugel blue g1hcsrr0484 crospovidone lactose monohydrate magnesium stearate opacode white s-1-7085 - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).